(Q37955231)

25 August 2017

A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms (English)

1 reference

25 August 2017

Hans Carl Hasselbalch

series ordinal

1

1 reference

25 August 2017

1 December 2011

1 reference

Expert Review of Hematology

25 August 2017

19

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

25 August 2017

4

1 reference

25 August 2017

637-655

1 reference

25 August 2017

6

1 reference

Virus interference. I. The interferon

25 August 2017

1 reference

Evolution of the Class 2 cytokines and receptors, and discovery of new friends and relatives

21 January 2018

1 reference

Mechanisms of type-I- and type-II-interferon-mediated signalling

21 January 2018

1 reference

Type I interferon receptors: biochemistry and biological functions.

21 January 2018

1 reference

The interferons: 50 years after their discovery, there is much more to learn

21 January 2018

1 reference

Stimulation of naïve and memory T cells by cytokines

21 January 2018

1 reference

Interferon therapy in myelomatosis

21 January 2018

1 reference

The role of interferon-alpha in the treatment of chronic myeloid leukemia

21 January 2018

1 reference

High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a

21 January 2018

1 reference

Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.

21 January 2018

1 reference

Sustained major molecular response on interferon alpha-2b in two patients with polycythemia vera.

21 January 2018

1 reference

Myelofibrosis with myeloid metaplasia: the advanced phase of an untreated disseminated hematological cancer. Time to change our therapeutic attitude with early upfront treatment?

21 January 2018

1 reference

Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis.

21 January 2018

1 reference

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera

21 January 2018

1 reference

Redefining the role of interferon in the treatment of malignant diseases

21 January 2018

1 reference

Complete molecular remission in a polycythaemia vera patient 12 years after discontinuation of interferon-alpha.

21 January 2018

1 reference

The renaissance of interferon therapy for the treatment of myeloid malignancies

21 January 2018

1 reference

Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report.

21 January 2018

1 reference

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

21 January 2018

1 reference

Interferon alpha for treatment of chronic myeloid leukemia

21 January 2018

1 reference

Interferon treatment in patients with hypereosinophilia

21 January 2018

1 reference

Interferon-α in acute myeloid leukemia: an old drug revisited

21 January 2018

1 reference

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group

21 January 2018

1 reference

Interferon-alpha in the treatment of multiple myeloma

21 January 2018

1 reference

Interferons alpha and beta as immune regulators--a new look

21 January 2018

1 reference

Review: Milstein Award lecture: interferons and cancer: where from here?

21 January 2018

1 reference

Interferons at age 50: past, current and future impact on biomedicine

21 January 2018

1 reference

Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity.

21 January 2018

1 reference

Inactivation of Stat3 in tumor cells: releasing a brake on immune responses against cancer?

21 January 2018

1 reference

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

21 January 2018

1 reference

The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse

21 January 2018

1 reference

The STATs of cancer--new molecular targets come of age

21 January 2018

1 reference

The role of STATs in transcriptional control and their impact on cellular function

21 January 2018

1 reference

Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects

21 January 2018

1 reference

Influence of interferon-alpha on cytokine expression by the bone marrow microenvironment--impact on treatment of myeloproliferative disorders

21 January 2018

1 reference

Efficacy and safety of human leucocyte interferon-alpha treatment in patients younger than 60 years of age with polycythaemia vera

21 January 2018

1 reference

Symptoms, symptom distress and health-related quality of life in patients with polycythaemia vera or essential thrombocythaemia during treatment with interferon-alpha

21 January 2018

1 reference

Analysis of the antiviral activities of natural IFN-alpha preparations and their subtype compositions

21 January 2018

1 reference

A species of human alpha interferon that lacks the ability to boost human natural killer activity

21 January 2018

1 reference

Resistance to Recombinant Interferon Alfa-2a in Hairy-Cell Leukemia Associated with Neutralizing Anti-Interferon Antibodies

21 January 2018

1 reference

Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naïve patients with hepatitis C virus infection: meta-analysis of randomized controlled trials

21 January 2018

1 reference

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

21 January 2018

1 reference

A long-term clinical trial of interferon alpha-therapy in essential thrombocythemia

21 January 2018

1 reference

Interferon in essential thrombocythaemia

21 January 2018

1 reference

Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia

21 January 2018

1 reference

Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders

21 January 2018

1 reference

A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.

21 January 2018

1 reference

Development of pegylated interferons for the treatment of chronic hepatitis C.

21 January 2018

1 reference

Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation

21 January 2018

1 reference

The role of alpha-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): a concise update

21 January 2018

1 reference

Interferon alpha in the treatment of polycythemia vera

21 January 2018

1 reference

The role of interferon-alpha in the treatment of idiopathic myelofibrosis

21 January 2018

1 reference

Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.

21 January 2018

1 reference

Prognostic significance of autoimmunity during treatment of melanoma with interferon.

21 January 2018

1 reference

Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.

21 January 2018

1 reference

Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.

21 January 2018

1 reference

Pregnancy and its management in the Philadelphia negative myeloproliferative diseases

21 January 2018

1 reference

Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe

21 January 2018

1 reference

Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy

21 January 2018

1 reference

Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation

21 January 2018

1 reference

Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis

21 January 2018

1 reference

A critical reappraisal of the WHO classification of the chronic myeloproliferative disorders

21 January 2018

1 reference

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes

21 January 2018

1 reference

Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden

21 January 2018

1 reference

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype

21 January 2018

1 reference

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

21 January 2018

1 reference

Clinical correlates of JAK2V617F allele burden in essential thrombocythemia

21 January 2018

1 reference

Biomarker analysis in polycythemia vera under interferon-alpha treatment: clonality, EEC, PRV-1, and JAK2 V617F.

21 January 2018

1 reference

Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells

21 January 2018

1 reference

IFNalpha activates dormant haematopoietic stem cells in vivo.

21 January 2018

1 reference

Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion.

21 January 2018

1 reference

Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders.

21 January 2018

1 reference

Alfa-interferon in the treatment of essential thrombocythemia: clinical results and evaluation of its biological effects on the hematopoietic neoplastic clone. Italian Cooperative Group on ET.

21 January 2018

1 reference

Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa

21 January 2018

1 reference

Efficacy of recombinant interferon-alpha (rIFN-alpha) in polycythaemia vera: a study of 17 patients and an analysis of published data

21 January 2018

1 reference

Minimal residual disease and normalization of the bone marrow after long-term treatment with alpha-interferon2b in polycythemia vera. A report on molecular response patterns in seven patients in sustained complete hematological remission

21 January 2018

1 reference

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

21 January 2018

1 reference

Awakening dormant haematopoietic stem cells

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/EHM.11.63

1 reference

25 August 2017

1 reference

PubMed ID

22077528